2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Prostatic Neoplasms
4
Neoplasm Metastasis
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Vaping
1
Urinary Bladder Neoplasms
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Solid Tumor
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Interventions
Injections
26
toripalimab
17
pembrolizumab
17
tislelizumab
12
Gemcitabine
8
Cisplatin
7
spartalizumab
6
atezolizumab
6
Irinotecan
6
Carboplatin
6
Paclitaxel
5
Oxaliplatin
5
Nivolumab
5
Leucovorin
5
Fluorouracil
5
camrelizumab
4
Pemetrexed
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
trastuzumab deruxtecan
3
sintilimab
3
olaparib
3
lenvatinib
3
cediranib
3
PM 01183
3
Drug Therapy
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
BID protein, human
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts